U.S. markets closed

Mylan N.V. (MYL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.42+0.21 (+1.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close14.21
Bid14.35 x 1800
Ask14.43 x 3200
Day's Range14.09 - 14.47
52 Week Range12.75 - 23.11
Avg. Volume5,049,182
Market Cap7.454B
Beta (5Y Monthly)1.51
PE Ratio (TTM)27.52
EPS (TTM)0.52
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 27, 2007
1y Target Est22.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX

    On September 25, 2020, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0528 per share to shareholders of record at the close of business on September 18, 2020.

  • Reuters

    Milan judge seizes 2.3 mln euros from Novartis in fraud probe

    A Milan judge has seized 2.3 million euros ($2.7 million) from pharmaceutical multinational Novartis as part of a fraud investigation, a document seen by Reuters shows. The money has been sequestered from the company's Italian unit Novartis Farma SpA, suspected of selling medicines to hospitals at inflated prices as part of a scheme to fraudulently obtain reimbursement funds from the regional government. Novartis said in a statement it rejected the "groundless" accusations of the Milan prosecutors and had behaved with full transparency.

  • Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

    Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

    The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.